Where is Merck & Co. (MRK) Headed According to Analysts?

Group 1 - Merck & Co., Inc. (NYSE:MRK) is currently viewed as one of the best drug stocks to buy, with a bullish stance from analysts [1] - The company has a strategic position in the competitive landscape of antibody-drug conjugates (ADCs) for treating extensive-stage small cell lung cancer (ES-SCLC) [2] - J.P. Morgan analyst Chris Schott has set a price target of $120.00 for Merck, maintaining a Buy rating [2] Group 2 - The analyst consensus for Merck is a Moderate Buy, with a median price target of $82.81, indicating a potential upside of 20.76% from current levels [3] - Merck operates as a biopharmaceutical company, providing health solutions for the treatment and prevention of diseases in both animals and humans [3] - The company's Pharmaceutical segment offers vaccines and human health pharmaceutical products, while its Animal Health segment focuses on vaccines and veterinary pharmaceutical products [4]